Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks
Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone : a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001
Heinrich, Michael C; Joensuu, Heikki; Demetri, George D; Corless, Christopher L; Apperley, Jane; Fletcher, Jonathan A; Soulieres, Denis; Dirnhofer, Stephan; Harlow, Amy; Town, Ajia; McKinley, Arin; Supple, Shane G; Seymour, John; Di Scala, Lilla; van Oosterom, Allan; Herrmann, Richard; Nikolova, Zariana; McArthur, And Grant; Imatinib Target Exploration Consortium Study B2225
2008
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases
Koeberle, Dieter; Saletti, Piercarlo; Borner, Markus; Gerber, Daniela; Dietrich, Daniel; Caspar, Clemens B; Mingrone, Walter; Beretta, Kurt; Strasser, Florian; Ruhstaller, Thomas; Mora, Oreste; Herrmann, Richard; Swiss Group for Clinical Cancer Research
2008
Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine : a multicenter, phase II trial of the swiss group for clinical cancer research
Laffer, U; Metzger, U; Aeberhard, P; Lorenz, M; Harder, F; Maibach, R; Zuber, M; Herrmann, R
2008
Adjuvant perioperative portal vein or peripheral intravenous chemotherapy for potentially curative colorectal cancer : long-term results of a randomized controlled trial
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer : a multicenter, single-arm phase II trial (SAKK 24/06)
Annals of oncology
JournalItem (Kommentare, Editorials, Rezensionen, Urteilsanmerk., etc. in einer wissensch. Zeitschr.